# Hybrid Immunotherapy for Hemophagocytic LymphoHistiocytosis

> **NCT01104025** · PHASE2 · COMPLETED · sponsor: **Children's Hospital Medical Center, Cincinnati** · enrollment: 31 (actual)

## Conditions studied

- Hemophagocytic Lymphohistiocytosis

## Interventions

- **DRUG:** ATG, rabbit
- **DRUG:** Etoposide
- **DRUG:** Methotrexate
- **DRUG:** hydrocortisone
- **DRUG:** Dexamethasone

## Key facts

- **NCT ID:** NCT01104025
- **Lead sponsor:** Children's Hospital Medical Center, Cincinnati
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-04
- **Primary completion:** 2015-11
- **Final completion:** 2016-04
- **Target enrollment:** 31 (ACTUAL)
- **Last updated:** 2020-10-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01104025

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01104025, "Hybrid Immunotherapy for Hemophagocytic LymphoHistiocytosis". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT01104025. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*